Inhibitory effects of caspase inhibitors on the activity of matrix metalloproteinase (MMP)‐2

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Biochemical Pharmacology

• Publication date

  2012-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.bcp.2013.06.003PMID 23774623
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanisms of cytosolic targeting of matrix metalloproteinase‐2

  2012cited by this paper
• Calpain inhibitors exhibit matrix metalloproteinase-2 inhibitory activity.

  2012cited by this paper
• Caspase substrates and cellular remodeling.

  2011cited by this paper
• Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertension.

  2011cited by this paper
• Structure of human caspase-6 in complex with Z-VAD-FMK: New peptide binding mode observed for the non-canonical caspase conformation.

  2011cited by this paper
• Caspase-dependent protein phosphatase 2A activation contributes to endotoxin-induced cardiomyocyte contractile dysfunction*

  2010cited by this paper
• Titin is a Target of Matrix Metalloproteinase-2: Implications in Myocardial Ischemia/Reperfusion Injury

  2010cited by this paper
• Activation and modulation of 72kDa matrix metalloproteinase-2 by peroxynitrite and glutathione.

  2009cited by this paper
• Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins.

  2009cited by this paper
• Inhibition of matrix metalloproteinase-2 by PARP inhibitors.

  2009cited by this paper
• Some commonly used caspase substrates and inhibitors lack the specificity required to monitor individual caspase activity.

  2008cited by this paper
• Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury.

  2007cited by this paper
• Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches.

  2007cited by this paper
• Blockade of hypoxia-reoxygenation-mediated collagen type I expression and MMP activity by overexpression of TGF-beta1 delivered by AAV in mouse cardiomyocytes.

  2007cited by this paper
• Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction.

  2007cited by this paper
• Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases

  2007cited by this paper
• Caspase inhibitors: viral, cellular and chemical

  2007cited by this paper
• Discovery and Characterization of a Novel Inhibitor of Matrix Metalloprotease-13 That Reduces Cartilage Damage in Vivo without Joint Fibroplasia Side Effects*

  2007cited by this paper
• Cell suicide and caspases.

  2007cited by this paper
• Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides.

  2006cited by this paper
• Hepatic ischemia/reperfusion injury is prevented by a novel matrix metalloproteinase inhibitor, ONO-4817.

  2006cited by this paper
• Caspases: pharmacological manipulation of cell death.

  2005cited by this paper
• Degradation of Myosin Light Chain in Isolated Rat Hearts Subjected to Ischemia-Reperfusion Injury: A New Intracellular Target for Matrix Metalloproteinase-2

  2005cited by this paper
• Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity.

  2004cited by this paper
• New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2).

  2004influential reference
• ONO-4817, a novel matrix metalloproteinase inhibitor, attenuates allograft vasculopathy in a rat cardiac transplant.

  2004cited by this paper
• Caspase Inhibition Attenuates Contractile Dysfunction Following Cardioplegic Arrest and Rewarming in the Setting of Left Ventricular Failure

  2004influential reference
• Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction.

  2003cited by this paper
• Reperfusion, not simulated ischemia, initiates intrinsic apoptosis injury in chick cardiomyocytes.

  2003influential reference
• Intracellular Action of Matrix Metalloproteinase-2 Accounts for Acute Myocardial Ischemia and Reperfusion Injury

  2002cited by this paper
• Functional consequences of caspase activation in cardiac myocytes

  2002cited by this paper
• Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2.

  2002cited by this paper
• Inhibition of caspase-3 improves contractile recovery of stunned myocardium, independent of apoptosis-inhibitory effects.

  2001influential reference
• Non-specific caspase inhibition reduces infarct size and improves post-ischaemic recovery in isolated ischaemic/reperfused rat hearts

  2001influential reference
• Caspase activation and mitochondrial cytochrome C release during hypoxia-mediated apoptosis of adult ventricular myocytes.

  2000influential reference
• ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs

  2000cited by this paper
• Non‐specific effects of methyl ketone peptide inhibitors of caspases

  1999cited by this paper
• Staurosporine-induced apoptosis in cardiomyocytes: A potential role of caspase-3.

  1998cited by this paper
• This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba

  year unknowncited by this paper

• MMP-2 inhibition attenuates ER stress-mediated cell death during myocardial ischemia-reperfusion injury by preserving IRE1α.

  2024cites this paper
• Role of pyroptosis in the pathogenesis and treatment of diseases

  2023cites this paper
• The roles of intracellular proteolysis in cardiac ischemia–reperfusion injury

  2023influential citation
• Identifying simultaneous matrix metalloproteinases/soluble epoxide hydrolase inhibitors

  2021cites this paper
• Ursolic acid reduces hepatocellular apoptosis and alleviates alcohol-induced liver injury via irreversible inhibition of CASP3 in vivo

  2020cites this paper
• Caspase inhibitors: a review of recently patented compounds (2013-2015)

  2018cites this paper
• Mechanisms of Cardiac Cell Death

  2016cites this paper
• Matrix Metalloproteinases (MMP), a Major Responsible Downstream Signaling Molecule for Cellular Damage - A Review

  2016cites this paper
• Cardiomyocytes – Active Players in Cardiac Disease

  2016cites this paper
• CRM197 in Combination With shRNA Interference of VCAM‐1 Displays Enhanced Inhibitory Effects on Human Glioblastoma Cells

  2015cites this paper
• Degradation of cardiac myosin light chain kinase by matrix metalloproteinase-2 contributes to myocardial contractile dysfunction during ischemia/reperfusion.

  2014cites this paper
• Myocardial matrix metalloproteinase-2: inside out and upside down.

  2014cites this paper